Pharmafile Logo
Pharmafocus logo
Advanced Search

Medivation

Showing 13 posts of 28 posts found.

amgen_flag

Amgen looking to join the fray, mulling Medivation bid – Reports

May 5, 2016
Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …

News
sanofi_hq__boetie_hall

Sanofi sends letter to Medivation board; claims shareholders want takeover

May 5, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover

The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …

News

Pfizer joins the race, bids for Medivation – Reports

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …

News
sanofi_hq__boetie_hall

Board at Medivation unanimously reject Sanofi bid

April 29, 2016
Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover

The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …

News

Sanofi makes unsolicited $9.8 billion bid for Medivation

April 28, 2016
Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer

French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …

News
astrazeneca_building_white

AstraZeneca hold internal talks for Medivation takeover – reports

April 18, 2016
Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover

AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …

News

US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi

March 30, 2016
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price

US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …

News
logo

Phase III trial initiated for enzalutamide in treatment of prostate cancer

March 24, 2016
Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer

Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …

News

FDA approves new indication for Xtandi

September 11, 2014
Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate

The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …

News

Astellas submits new prostate cancer drug to EMA

June 28, 2012
Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide

Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …

News

Prostate cancer drug extends life after chemotherapy

March 29, 2012
Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer

Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …

News
Pfizer image

Pfizer pulls plug on Alzheimer’s drug

January 18, 2012
Research and Development, Sales and Marketing Medivation, Pfizer, dimebon

Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure.  The firms said a 12-month …

News

Pfizer suffers Alzheimer’s setback

March 4, 2010
Research and Development Alzheimer's, Medivation, Pfizer

Pfizer has suffered a big setback with the oral Alzheimer’s disease treatment it is developing with biotech outfit Medivation. Investigational …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026